Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
-
Field
-
to start a PhD trajectory in liquid biopsy method development for improved cancer detection. The project has a strong focus on novel design and implementation of different IT tools and coordination of team
-
clinical potential of altered lipid metabolism in prostate cancer (PCa). Applicants can choose from 9 interconnected PhD projects, along the research pipeline. DC1-3 will generate a comprehensive and spatial
-
PhD position in the context of an interdisciplinary FWO research project: “Plasma-treated hydrogels as a new selective therapy for head and neck cancer” ABOUT GHENT UNIVERSITY Ghent University is a
-
researchers and informs the public on the impact of biotechnology on human health. PhD projects Multi-ome exploration of different liquid biopsy fractions for cancer diagnosis and monitoring - Lab De Preter
-
within a Research Infrastructure? No Offer Description PhD Research position: multi-omics liquid biopsy platform to advance precision cancer medicine. (ref. BAP-2024-251). Details: https
-
%) doctoral scholarship holder in the field of signal enhancement strategies for photoelectrochemical sensors for nucleic acid-based sequences. The overall goal of this PhD is the development of strategies
-
for biomedical applications. In order to strive for academic excellence driven by international collaboration, this project will be a joint PhD, supervised by Prof. Karolien De Wael (A-PECS) and Prof. John Mack
-
staff and students. Job description We are looking for a highly motivated PhD candidate to develop and study plasma-treated hydrogels used in the treatment of head and neck cancer in a joint project
-
. The overall goal of this PhD is the development of advanced data models to extract qualitative and quantitative information from electrochemical data. These data models will improve the state-of-the-art in (bio
-
design novel immunotherapies to prevent relapse in acute myeloid leukemia (AML), an aggressive and common form of hematological cancer. The most promising immunotherapeutic strategies will be tested in